Guidance on health economic modelling of personalised medicine in Europe and review of evidence of the value of personalised

Lead partner: iMTA

WP1 will:

  • Provide a systematic review of existing model-based economic evaluations of personalised medicine, considering the specific modelling characteristics that are required to fully represent the (value of) treatment pathways in personalised medicine
  • Identify best practices of health economic modelling of personalised medicine
  • Develop guidance on health economic modelling of personalised medicine to inform pricing and reimbursement decisions and clinical guidelines
  • Conclude on current estimates of the value of personalised medicine
Work progress WP1 (start 2019, duration 15 months)
67%